Nirohshah Trialonis-Suthakharan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nirohshah Trialonis-Suthakharan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Christine Bundy
School of Healthcare Sciences, Cardiff University , Cardiff
4 shared publications - Matthias Augustin
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE) Hamburg Deutschland
4 shared publications - Rachael Pattinson
School of Dentistry Cardiff University Cardiff UK
4 shared publications - Jennifer Austin
International Alliance of Dermatology Patient Organizations Ottawa Ontario Canada
3 shared publications - Nick Courtier
School of Healthcare Sciences Cardiff University Cardiff UK
3 shared publications - Rachael Marie Hewitt
School of Healthcare Sciences Cardiff University Cardiff UK
3 shared publications
Latest Publications
- Open Access
- 27 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (6) , 936-948
Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure
Background: Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people’s lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility. Objectives: To test the remaining measurement properties of the PRIDD and establish the interpretability of scores against the COSMIN criteria, using classic and modern psychometric methods. Methods: A global longitudinal study consisting of two online surveys administered 2–4 weeks apart was carried out. Adults (≥ 18 years of age) living with a dermatological condition were recruited via the International Alliance of Dermatology Patient Organizations’ (GlobalSkin) membership network. Participants completed PRIDD, a demographics questionnaire and other related measures, including the Dermatology Life Quality Index. We tested the criterion validity, construct validity and responsiveness (Spearman’s ρ, independent-samples t-tests and Anova); test–retest reliability [interclass correlation coefficient (ICC)]; measurement error [smallest detectable change or limits of agreement (LoA), distribution-based minimally important change (MIC)]; floor and ceiling effects (number of minimum and maximum scores and person–item location distribution maps), score bandings (κ coefficient of agreement) and the anchor-based MIC of the PRIDD. Results: In total, 504 people with 35 dermatological conditions from 38 countries participated. Criterion validity (ρ = 0.79), construct validity (76% hypotheses met), test–retest validity (ICC = 0.93) and measurement error (LoA = 1.3 < MIC = 4.14) were sufficient. Floor and ceiling effects were in the acceptable range (< 15%). Score bandings were determined (κ = 0.47); however, the anchor-based MIC could not be calculated owing to an insufficient anchor. Conclusions: PRIDD is a valid and reliable tool to evaluate the impact of dermatological disease on people’s lives in research and clinical practice. It is the first dermatology-specific PROM to meet the COSMIN criteria. These results support the value of developing and validating PROMs with a patient-centred approach and using classic and modern psychometric methods. Further testing of responsiveness and MIC, cross-cultural translation, linguistic validation and global data collection are planned.
- 27 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (6) , 936-948
Open AccessMeasurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure
Background: Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people’s lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility. Objectives: To test the remaining measurement properties of the PRIDD and establish the interpretability of scores against the COSMIN criteria, using classic and modern psychometric methods. Methods: A global longitudinal study consisting of two online surveys administered 2–4 weeks apart was carried out. Adults (≥ 18 years of age) living with a dermatological condition were recruited via the International Alliance of Dermatology Patient Organizations’ (GlobalSkin) membership network. Participants completed PRIDD, a demographics questionnaire and other related measures, including the Dermatology Life Quality Index. We tested the criterion validity, construct validity and responsiveness (Spearman’s ρ, independent-samples t-tests and Anova); test–retest reliability [interclass correlation coefficient (ICC)]; measurement error [smallest detectable change or limits of agreement (LoA), distribution-based minimally important change (MIC)]; floor and ceiling effects (number of minimum and maximum scores and person–item location distribution maps), score bandings (κ coefficient of agreement) and the anchor-based MIC of the PRIDD. Results: In total, 504 people with 35 dermatological conditions from 38 countries participated. Criterion validity (ρ = 0.79), construct validity (76% hypotheses met), test–retest validity (ICC = 0.93) and measurement error (LoA = 1.3 < MIC = 4.14) were sufficient. Floor and ceiling effects were in the acceptable range (< 15%). Score bandings were determined (κ = 0.47); however, the anchor-based MIC could not be calculated owing to an insufficient anchor. Conclusions: PRIDD is a valid and reliable tool to evaluate the impact of dermatological disease on people’s lives in research and clinical practice. It is the first dermatology-specific PROM to meet the COSMIN criteria. These results support the value of developing and validating PROMs with a patient-centred approach and using classic and modern psychometric methods. Further testing of responsiveness and MIC, cross-cultural translation, linguistic validation and global data collection are planned.
- Open Access
- 24 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (7) , 1391-1400
Patient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study
Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient‐Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD measures the impact of dermatological conditions on the patient's life.Objectives: This study aimed to seek consensus from patients on which items to prioritize for inclusion in PRIDD.Methods: A modified, two‐round Delphi study was conducted. Adults (≥18 years) with dermatological conditions were recruited. The survey consisted of a demographic's questionnaire and 263 potential impact items in six languages. Quantitative data used Likert‐type ranking scales and analysed against consensus criteria. Qualitative data collected free text responses for additional feedback and a framework analysis was conducted.Results: 1154 people representing 90 dermatological conditions from 66 countries participated. Items were either removed (n = 79), edited (n = 179) or added (n = 2), based on consensus thresholds and qualitative feedback. Results generated the first draft of PRIDD with 27 items across five impact domains.Conclusion: This Delphi study resulted in the draft version of PRIDD, ready for psychometric testing. The triangulated data helped refine the existing conceptual framework of impact. PRIDD has since been pilot tested with patients and is currently undergoing psychometric testing.
- 24 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (7) , 1391-1400
Open AccessPatient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study
Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient‐Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD measures the impact of dermatological conditions on the patient's life.Objectives: This study aimed to seek consensus from patients on which items to prioritize for inclusion in PRIDD.Methods: A modified, two‐round Delphi study was conducted. Adults (≥18 years) with dermatological conditions were recruited. The survey consisted of a demographic's questionnaire and 263 potential impact items in six languages. Quantitative data used Likert‐type ranking scales and analysed against consensus criteria. Qualitative data collected free text responses for additional feedback and a framework analysis was conducted.Results: 1154 people representing 90 dermatological conditions from 66 countries participated. Items were either removed (n = 79), edited (n = 179) or added (n = 2), based on consensus thresholds and qualitative feedback. Results generated the first draft of PRIDD with 27 items across five impact domains.Conclusion: This Delphi study resulted in the draft version of PRIDD, ready for psychometric testing. The triangulated data helped refine the existing conceptual framework of impact. PRIDD has since been pilot tested with patients and is currently undergoing psychometric testing.
- Open Access
- 8 October 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (S7) , 40-50
Patient prioritisation of impact items to develop the patient‐reported impact of dermatological diseases (PRIDD) measure: European Delphi data
Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient‐reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.Methods: We conducted a modified, two rounds Delphi study, testing the outcomes from the previous qualitative interview study. Adults (≥18 years) living with a dermatological disease were recruited through the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. The survey consisted of a demographic questionnaire and 263 impact items and was available in six languages. Quantitative data were collected using ranking scales and analysed against a priori consensus criteria. Qualitative data were collected using free‐text responses and a Framework Analysis was conducted. European data were obtained, and descriptive statistics, including multiple subgroup analyses, were performed.Results: Out of 1154 participants, 441 Europeans representing 46 dermatological disease from 25 countries participated. The results produced a list of the top 20 impacts reported by European patients, with psychological impacts accounting for the greatest proportion.Conclusion: This study identified what patients consider to be the most important issues impacting their lives as a result of their dermatological disease. The data support previous evidence that patients experience profound psychological impacts and require psychological support. The findings can inform research, clinical practice and policy by indicating research questions and initiatives that are of most benefit to patients.
- 8 October 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (S7) , 40-50
Open AccessPatient prioritisation of impact items to develop the patient‐reported impact of dermatological diseases (PRIDD) measure: European Delphi data
Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient‐reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.Methods: We conducted a modified, two rounds Delphi study, testing the outcomes from the previous qualitative interview study. Adults (≥18 years) living with a dermatological disease were recruited through the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. The survey consisted of a demographic questionnaire and 263 impact items and was available in six languages. Quantitative data were collected using ranking scales and analysed against a priori consensus criteria. Qualitative data were collected using free‐text responses and a Framework Analysis was conducted. European data were obtained, and descriptive statistics, including multiple subgroup analyses, were performed.Results: Out of 1154 participants, 441 Europeans representing 46 dermatological disease from 25 countries participated. The results produced a list of the top 20 impacts reported by European patients, with psychological impacts accounting for the greatest proportion.Conclusion: This study identified what patients consider to be the most important issues impacting their lives as a result of their dermatological disease. The data support previous evidence that patients experience profound psychological impacts and require psychological support. The findings can inform research, clinical practice and policy by indicating research questions and initiatives that are of most benefit to patients.
- Open Access
- 5 September 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102
Development of a Conceptual Framework for a Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure: A Qualitative Concept Elicitation Study
Existing patient-reported outcome measures cannot comprehensively capture the full impact of living with a dermatological condition. The aim of this study was to develop a conceptual framework on which to build a new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. Adults (≥ 18 years of age) living with a dermatological condition, worldwide and/or representatives from a patient organization [AQ2] via a global patient organization network, were invited to an individual or group interview. Data were analysed thematically. Sixty-five people from 29 countries, representing 29 dermatological conditions, participated. Key themes were: (i) impacts at the individual, organizational and societal levels; (ii) impacts were point-in-time and cumulative; and (iii) impact is a multifaceted construct, with 2 subthemes (iiia) common impacts and (iiib) psychological and social impacts are most significant. The conceptual framework shows that impact is a multifaceted concept presenting across physical, psychological, social, financial, daily functioning and healthcare, and provides the basis for co-constructing the PRIDD with patients.
- 5 September 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102
Open AccessDevelopment of a Conceptual Framework for a Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure: A Qualitative Concept Elicitation Study
Existing patient-reported outcome measures cannot comprehensively capture the full impact of living with a dermatological condition. The aim of this study was to develop a conceptual framework on which to build a new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. Adults (≥ 18 years of age) living with a dermatological condition, worldwide and/or representatives from a patient organization [AQ2] via a global patient organization network, were invited to an individual or group interview. Data were analysed thematically. Sixty-five people from 29 countries, representing 29 dermatological conditions, participated. Key themes were: (i) impacts at the individual, organizational and societal levels; (ii) impacts were point-in-time and cumulative; and (iii) impact is a multifaceted construct, with 2 subthemes (iiia) common impacts and (iiib) psychological and social impacts are most significant. The conceptual framework shows that impact is a multifaceted concept presenting across physical, psychological, social, financial, daily functioning and healthcare, and provides the basis for co-constructing the PRIDD with patients.